Study of Predictors of Failure of Sulprostone Treatment in Postpartum Hemorrhage
NALAPOST
1 other identifier
observational
300
1 country
1
Brief Summary
The investigators wish to identify potential factors predicting failure of second-line drug treatment (sulproston (Nalador®)): risk factors and factors linked to a failure to take initial care for PPH. A better understanding of the aggravating factors of HPP and more particularly the factors inherent to the initial care would make it possible to think of ways to improve practices.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2020
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 19, 2020
CompletedFirst Submitted
Initial submission to the registry
November 2, 2020
CompletedFirst Posted
Study publicly available on registry
December 11, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 19, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
April 19, 2024
CompletedDecember 27, 2024
December 1, 2024
3.5 years
November 2, 2020
December 23, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
This a rétrospective study trayning to identify a potential predictors of failure of second-line drug treatment in the case of severe postpartum hemorrhage
1 year
Eligibility Criteria
Adult person (≥18 years old) who gave birth at HUS or at Poissy Saint-Germain-en Laye university hospital between 01/01/2019 and 12/31/2020 and having presented a postpartum hemorrhage treated with Sulprostone
You may qualify if:
- Major subject (≥18 years old)
- Subject having given birth at HUS or CHU Poissy Saint-Germain-en Laye between 01/01/2019 and 31/12/2020
- Subject having presented a postpartum haemorrhage treated with Sulprostone
- Subject not having expressed his opposition, after information, to the reuse of his data for the purposes of this research
You may not qualify if:
- Subject having expressed opposition to participating in the study
- Subject under guardianship or guardianship
- Subject under safeguard of justice
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
École de sages-femmes de Strasbourg
Strasbourg, Starsbourg, 67091, France
Related Publications (1)
Voillequin S, Meyer MN, Faraci F, Rozenberg MP, Rousseau A. Maternal and clinical characteristics associated with sulprostone failure in postpartum haemorrhage after vaginal delivery: A retrospective cohort study. Eur J Obstet Gynecol Reprod Biol. 2026 Feb;317:114862. doi: 10.1016/j.ejogrb.2025.114862. Epub 2025 Nov 28.
PMID: 41319511DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 2, 2020
First Posted
December 11, 2023
Study Start
October 19, 2020
Primary Completion
April 19, 2024
Study Completion
April 19, 2024
Last Updated
December 27, 2024
Record last verified: 2024-12